Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review

Autor: Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt L, Negro F, Piazzolla V, Santoro Rita, Dufour JF, Brunner B, Weber A, Herranz M, Mathieu A, Clerc O, Elisabetta D, Floriana F, Macera M, Pisaturo M, Stornaiuolo G, Rinaldi L, George JMix C, Cornberg M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3977::1fddcf53657c5da6a7197f7db8fa6ad6
http://hdl.handle.net/11591/396091

Valutazione del grasso midollare mediante Risonanza Magnetica Spettroscopica (1H-MRS) in donne con ipoparatiroidismo post-chirurgico. XIX Congresso nazionale SIOMMMS Bologna 24-26 ottobre 2019

Autor: Diacinti, Davide, Cipriani, C., Iannacone, A., Orlandi, M., Pepe, J., Colangelo, L., Piazzolla, V., Diacinti, D., Minisola, S.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3686::4c19437998f7c9beb5aef8fafa186eb2
http://hdl.handle.net/11573/1348279

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

Autor: Bruno, S, Bollani, S., Zignego, A. L., Pascasio, J. M., Magni, C., Ciancio, A., Caremani, M., Mangia, A., Marenco, S., Piovesan, S., Chemello, L., Babudieri, S., Moretti, A., Gea, F., Colletta, C., Perez Alvarez, R., Forns, X., Larrubia, J. R., Arenas, J., Crespo, J., Calvaruso, V., Ceccherini Silberstein, F., Maisonneuve, P., Craxì, A., Calleja, J. L., Di Marco, V., Monti, M., Rizzardini, G., Landonio, S., Rizzetto, M., Lapini, L. E., Piazzolla, V., Picciotto, A., Alberti, A., Cavaletto, L., Koch, M., Massari, M., Muratori, L., Cipriano, V., Montineri, A., Iacobello, C., Fangazio, S., Pirisi, M., Colombo, A., Bellati, G., Mazzotta, F., Pierotti, P., Traverso, A., Serviddio, G., Russello, M., Santantonio, T., Drenaggi, D., Marchionne, E., Zuin, M., Delliponti, M., Farina, F., Andreone, P., Scuteri, A., Galli, M., Giannini, EDOARDO GIOVANNI, Nerli, A., Carbonai, S., Coppola, N., Montalbano, M., Portelli, V., Di Biagio, A., Nicolini, LAURA AMBRA, Mastroianni, C., Madonia, S., Licata, A., Montalto, G., Giannitrapani, L., Mondelli, M., Pellicelli, A., Toniutto, P., Borgia, G., Gentile, I., De Luca, M., Di Costanzo, G. G., Corti, G., Sousa, M., Delgado, M. B., De La Revilla, J., Navarro, J. M., Barcena, R., Romero Gomez, M., Fernandez Rodriguez, C. M., Narvaez, I., Erdozain, J. C., Molina, E., Fernandez, I., Cuenca, B., Planas, R., Garcia Samaniego, J., Ladero, J. M., Gonzalez, J. M., Serra, M. A., Castellote, I., Sola, R., Anton, T., Ryan, I., Gonzalez, F., Martinez, E., Portu, J.

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55eee2a0c597fb9dbf1b0b00fe79cea9
http://hdl.handle.net/11390/1190517

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients with HCV genotype 3

Autor: Mangia, A, Bandiera, F, Mottola, L, Piazzolla, V, Minerva, N, Pellicelli, A, Ricci, GL, Cela, M, Carretta, V, Scotto, G, Bacca, D, Annichiarico, B, Romano, N, Russello, M, Barbarini, G, Agostinacchio, E, Andriulli, A., MONTALTO, Giuseppe

Background & Aims: The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established. Methods: Four hundred and fourteen patients received Peginterfer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3658::a029424a83129013ca6c92b7ce2935bd
http://hdl.handle.net/10447/52170

THU-323 - High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV)

Autor: Mangia, A., Piazzolla, V., Losappio, R., Mazzola, M., Visaggi, E., Bacca, D., Sogari, F., Potenza, D., Santoro, R., Carraturo, I., Tagarielli, V., Lauletta, G., Giannelli, A., Gesualdo, A., Minerva, N.

Publikováno v: In Journal of Hepatology April 2018 68 Supplement 1:S273-S274